Literature DB >> 15935358

Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients.

Bela F Asztalos1, Ernst J Schaefer, Katalin V Horvath, Caitlin E Cox, Sally Skinner, Jul Gerrior, Sherwood L Gorbach, Christine Wanke.   

Abstract

OBJECTIVE: To study the effects of HIV-infection and protease inhibitor (PI)-based highly active anti-retroviral therapy (HAART) on the lipid and high-density lipoprotein (HDL) subpopulation profile and to relate the changes to coronary heart disease (CHD)-risk. METHODS AND
DESIGN: The lipid and HDL subpopulation profiles of HIV-positive subjects (n = 48) were studied prospectively by comparing pre- and post-PI-HAART data as well as cross-section by comparing the profiles to HIV-negative subjects with (n = 96) and without CHD (n = 96).
RESULTS: HIV-infected HAART-naïve subjects had lower concentrations of low-density lipoprotein cholesterol (LDL-C) and HDL-C and higher concentration of triglycerides (TG) than healthy controls. After receiving PI-based HAART, LDL-C and TG concentrations increased, while HDL-C concentrations remained unchanged. The HDL subpopulation profiles of HAART-naïve HIV-positive patients were significantly different from those of healthy controls and were similar to those with CHD. Moreover, the HDL subpopulation profile changed unfavorably after PI-based HAART, marked with increased concentrations of the small, lipid-poor pre-beta-1 HDL (32% or 3.9 mg/dl; p < 0.001), and decreased concentration of the large, cholesterol-rich alpha-1 HDL (9% or 1 mg/dl ns).
CONCLUSION: An already unfavorable lipid and HDL subpopulation profile of HIV-positive HAART-naïve subjects further deteriorated after receiving PI-based treatment, which may cause increased CHD-risk in these subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15935358     DOI: 10.1016/j.atherosclerosis.2005.04.013

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  25 in total

Review 1.  Plant glutaredoxins: still mysterious reducing systems.

Authors:  N Rouhier; E Gelhaye; J-P Jacquot
Journal:  Cell Mol Life Sci       Date:  2004-06       Impact factor: 9.261

2.  [Coronary artery disease in HIV-infected subjects. Results of 101 coronary angiographies].

Authors:  T Neumann; K A Lülsdorf; P Krings; N Reinsch; R Erbel
Journal:  Herz       Date:  2010-12-23       Impact factor: 1.443

3.  Development of appropriate coronary heart disease risk prediction models in HIV-infected patients.

Authors:  Morris Schambelan; Peter W F Wilson; Kevin E Yarasheski; W Todd Cade; Victor G Dávila-Román; Ralph B D'Agostino; Tarek A Helmy; Matthew Law; Kristin E Mondy; Sharon Nachman; Linda R Peterson; Signe W Worm
Journal:  Circulation       Date:  2008-06-19       Impact factor: 29.690

4.  Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia.

Authors:  Anu Paranandi; Bela F Asztalos; Alexandra Mangili; Jefferey Kuvin; Jul Gerrior; Heidi Sheehan; Sally C Skinner; Alice M Tang; Christine A Wanke
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08       Impact factor: 2.205

5.  Short communication: risk of elevated total cholesterol/high-density lipoprotein cholesterol ratio after antiretroviral therapy in HIV/hepatitis C virus patients.

Authors:  Lisa Kakinami; Michael J Adams; Robert C Block; Susan E Cohn; Benedict Maliakkal; Susan G Fisher
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-10       Impact factor: 2.205

6.  Coronary Heart Disease (CHD) Risk Factors and Metabolic Syndrome in HIV-Positive Drug Users in Miami.

Authors:  Marianna K Baum; Carlin Rafie; Shenghan Lai; Lihua Xue; Sabrina Sales; J Bryan Page; Ronald Berkman; Linden Karas; Adriana Campa
Journal:  Am J Infect Dis       Date:  2006

7.  Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

Authors:  Daniel A Duprez; Lewis H Kuller; Russell Tracy; James Otvos; David A Cooper; Jennifer Hoy; Jacqueline Neuhaus; Nicholas I Paton; Nina Friis-Moller; Fiona Lampe; Angelike P Liappis; James D Neaton
Journal:  Atherosclerosis       Date:  2009-05-13       Impact factor: 5.162

8.  Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages.

Authors:  Weibin Zha; Guang Liang; Jian Xiao; Elaine J Studer; Phillip B Hylemon; William M Pandak; Guangji Wang; Xiaokun Li; Huiping Zhou
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

Review 9.  Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.

Authors:  Erdembileg Anuurad; Alison Semrad; Lars Berglund
Journal:  Metab Syndr Relat Disord       Date:  2009-10       Impact factor: 1.894

Review 10.  Infectious burden and atherosclerosis: A clinical issue.

Authors:  Rosa Sessa; Marisa Di Pietro; Simone Filardo; Ombretta Turriziani
Journal:  World J Clin Cases       Date:  2014-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.